Principia Biopharma is a privately held biopharmaceutical company based in South San Francisco, Calif., focused on discovering and developing first-in-class small-molecule drugs for autoimmune diseases and oncology. The company’s core technology—reversible covalent small-molecule inhibitors, licensed from the University of California, San Francisco—aims to produce highly selective, antibody-like specificity against kinases and other challenging targets. Its pipeline includes an oral BTK inhibitor for potential use in autoimmune disease and oncology, an oral selective irreversible FGFR inhibitor program for the treatment of solid tumors, and an oral IL-17 pathway inhibitor program with utility across a range of autoimmune and inflammatory diseases. Principia plans to use financing proceeds to further advance these programs and to expand into a clinical-stage company. Financially, Principia completed a $50 million Series B and had previously raised $40 million in a Series A. The company states its tailored covalent approach could enable efficacious drugs with enhanced safety margins suitable for chronic therapies. Principia Biopharma focuses on the discovery and development of differentiated small‑molecule drugs targeting inflammatory and autoimmune diseases as well as cancer. The company develops programs enabled by its reversible covalent platform and is advancing a lead molecule toward the clinic. Principia expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and the platform. Leadership is led by CEO Martin Babler with Jens Oliver Funk, M.D. as CSO. The company is based in South San Francisco, CA. Recent financings have supported preclinical and development activities for its pipeline.

Total raised

$63M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2014